190 related articles for article (PubMed ID: 35665759)
1. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.
Maekawa N; Konnai S; Asano Y; Sajiki Y; Deguchi T; Okagawa T; Watari K; Takeuchi H; Takagi S; Hosoya K; Kim S; Ohta H; Kato Y; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2022 Jun; 12(1):9265. PubMed ID: 35665759
[TBL] [Abstract][Full Text] [Related]
2. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E
Sajiki Y; Konnai S; Okagawa T; Nishimori A; Maekawa N; Goto S; Ikebuchi R; Nagata R; Kawaji S; Kagawa Y; Yamada S; Kato Y; Nakajima C; Suzuki Y; Murata S; Mori Y; Ohashi K
Infect Immun; 2018 May; 86(5):. PubMed ID: 29483289
[TBL] [Abstract][Full Text] [Related]
4. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N; Konnai S; Nishimura M; Kagawa Y; Takagi S; Hosoya K; Ohta H; Kim S; Okagawa T; Izumi Y; Deguchi T; Kato Y; Yamamoto S; Yamamoto K; Toda M; Nakajima C; Suzuki Y; Murata S; Ohashi K
NPJ Precis Oncol; 2021 Feb; 5(1):10. PubMed ID: 33580183
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E
Sajiki Y; Konnai S; Okagawa T; Nishimori A; Maekawa N; Goto S; Watari K; Minato E; Kobayashi A; Kohara J; Yamada S; Kaneko MK; Kato Y; Takahashi H; Terasaki N; Takeda A; Yamamoto K; Toda M; Suzuki Y; Murata S; Ohashi K
J Immunol; 2019 Sep; 203(5):1313-1324. PubMed ID: 31366713
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Tang H; Liu Y; Wang C; Zheng H; Chen Y; Liu W; Chen X; Zhang J; Chen H; Yang Y; Yang J
J Pharmacol Exp Ther; 2019 Mar; 368(3):401-413. PubMed ID: 30591531
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.
Deguchi T; Maekawa N; Konnai S; Owaki R; Hosoya K; Morishita K; Nakamura M; Okagawa T; Takeuchi H; Kim S; Kinoshita R; Tachibana Y; Yokokawa M; Takagi S; Kato Y; Suzuki Y; Murata S; Ohashi K
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296981
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.
Wurster S; Albert ND; Bharadwaj U; Kasembeli MM; Tarrand JJ; Daver N; Kontoyiannis DP
Front Immunol; 2022; 13():838344. PubMed ID: 35251033
[TBL] [Abstract][Full Text] [Related]
11. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
Ugurel S; Schadendorf D; Horny K; Sucker A; Schramm S; Utikal J; Pföhler C; Herbst R; Schilling B; Blank C; Becker JC; Paschen A; Zimmer L; Livingstone E; Horn PA; Rebmann V
Ann Oncol; 2020 Jan; 31(1):144-152. PubMed ID: 31912789
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
13. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of PD-L1 Expression by Prostaglandin E
Goto S; Konnai S; Hirano Y; Kohara J; Okagawa T; Maekawa N; Sajiki Y; Watari K; Minato E; Kobayashi A; Gondaira S; Higuchi H; Koiwa M; Tajima M; Taguchi E; Uemura R; Yamada S; Kaneko MK; Kato Y; Yamamoto K; Toda M; Suzuki Y; Murata S; Ohashi K
Front Vet Sci; 2020; 7():12. PubMed ID: 32154274
[TBL] [Abstract][Full Text] [Related]
15. Reduced peripheral PGE2 biosynthesis in Plasmodium falciparum malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism.
Keller CC; Hittner JB; Nti BK; Weinberg JB; Kremsner PG; Perkins DJ
Mol Med; 2004; 10(1-6):45-54. PubMed ID: 15502882
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients.
Giunta EF; Barra G; De Falco V; Argenziano G; Napolitano S; Vitale P; Zanaletti N; Terminiello M; Martinelli E; Morgillo F; Ciardiello D; De Palma R; Ciardiello F; Troiani T
Sci Rep; 2020 Oct; 10(1):17626. PubMed ID: 33077770
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.
Sajiki Y; Konnai S; Cai Z; Takada K; Okagawa T; Maekawa N; Fujisawa S; Kato Y; Suzuki Y; Murata S; Ohashi K
Immunohorizons; 2020 Dec; 4(12):837-850. PubMed ID: 33443026
[TBL] [Abstract][Full Text] [Related]
19. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
20. Involvement of cyclooxygenase-2 in interleukin-1alpha-induced prostaglandin production by human periodontal ligament cells.
Noguchi K; Shitashige M; Ishikawa I
J Periodontol; 1999 Aug; 70(8):902-8. PubMed ID: 10476899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
